期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

浸润型导管癌中三阴乳腺癌的临床特征与预后 被引量：5

The clinicopathological feathures and outcome of triple negative breast cancer in invasive ductal breast cancer
下载PDF
导出
摘要 目的研究浸润性导管癌中三阴乳腺癌的临床病理特征及其预后。方法回顾性分析我院既有临床资料又有随访结果和蜡块的226例病例,对这226例石蜡标本切片行雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体(HER2)3种抗体的免疫组化染色,并通过电话或信件问卷随访。结果利用ER、PR、HER2 3种抗体的免疫组化结果,可将浸润性导管癌分为luminal A、luminal B、HER2过度表达、三阴和未分型5种类型。其中三阴乳腺癌46例(21.4%),组织学分级以Ⅲ级为多。三阴乳腺癌的肺、胸膜转移率高于luminal A型、luminal B型、HER2过度表达型和未分型(P均<0.05);腋窝淋巴结,锁骨上、下淋巴结转移率低于luminal A、luminal B和HER2过度表达型(P均<0.05)。三阴乳腺癌的疾病缓解率低于ER、PR均阳性的lu-minal A型(P<0.05),生存率低于ER、PR均阳性的luminalA型(P<0.05)和luminal B型(P<0.05)。结论三阴乳腺癌有其不同于其它类型乳腺癌的临床病理特征及转移途径,其预后明显低于ER、PR均阳性的乳腺癌。 Objective To explore the clinicopathological features and the clinical outcome of triple negative breast cancer. Methods A retrospective analysis was performed for 226 women diagnosed and treated for breast cancer in our hospital from 2001 to 2005 with all their clinicopathological features, blocks and follow-up data available. 226 slides were immunohistochemical stained by ER, PR, HER2 three antibodies. Results Invasive ductal breast cancer could be divided into 5 phenotypes （luminal A, luminal B, HER2 overexpression, triple-negative, and null） by using immunohistoehemieal staining with ER, PR, HER2 three antibodies. Triple-negative breast cancer account for 46 cases （21.4%）, its histological grade was prone to be grade Ⅲ. The rate of lung and pleural metastases in the triple-negative group was higher than that in luminal A, luminal B, HER2 overexpression and null groups （P 〈 0.05） ; The rates of axillary, supraclavicular and infraelavicular lymph nodes metastases in the triple-negative group were lower than that in luminal A, luminal B and HER2 overexpression groups. Triple-negative tumours were associated with shorter disease free-interval（DFI） than luminal A phenotype（both ER ＋ and PR ＋ ）（P 〈0. 05）, were associated with shorter overall survival（OS） than both luminal A phenotype（ ER ＋ and PR ＋ ） （P 〈0. 05） and luminal B phenotypes （ ER ＋ and PR ＋ ） （P 〈 0. 05 ）. Conclusion Triple negative breast cancer is an unique phenotype with its own clinicopathological features and metastases, the clinical outcome is much poorer than the other phenotypes with both ER, PR receptor positive.
作者 王星星 孟刚
机构地区 安徽医科大学病理学教研室
出处 《安徽医科大学学报》 CAS 北大核心 2009年第5期606-612,共7页 Acta Universitatis Medicinalis Anhui
关键词 肿瘤/导管/乳腺 免疫表型 预后 breast neoplasms carcinoma ductal breast immunophynotyping prognosis
分类号 R737.9 [医药卫生—肿瘤] R392 [医药卫生—免疫学]
  • 相关文献

参考文献16

  • 1Perou C M,Sorlie T,Eisen M B,et al.Molecular portraits of human breast tumors[J].Nature,2000,406(6797):747-52.
  • 2Sorlie T,Perou C M,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci USA,2001,98(19):10869-74.
  • 3Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets[J].Proc Natl Acad Sci USA,2003,100 (14):8418-23.
  • 4Heatley M,Maxwell P,Whiteside C,et al.Cytokeratin intermediate filament expression in benign and malignant breast disease[J].J Clin Pathol,1995,48(1):26-32.
  • 5Abd El-Rehim D M,Pinder S E,Paish C E,et al.Expression of luminal and basal cytokeratins in human breast carcinoma[J].J Pathol,2004,203 (2):661–71.
  • 6Fulford L G,Reis-Filho J S,Ryder K,et al.Basal-like grade Ⅲ invasive ductal carcinoma of the breast:patterns of metastasis and long-term survival[J].Breast Cancer Res,2007,9(1):R4.
  • 7Rakha E A,El-Sayed M E,Green A R,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32.
  • 8Sorlie T,Pemu C M,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci USA,2001,98(69):10869-74.
  • 9Dent R,Trudeau M,Pritchard K J,et al.Triple negative breast cancer.Clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13 (15 Pt 1):4429-34.
  • 10罗玉环,孟刚.BAG-1在乳腺癌中的表达及其意义[J].安徽医科大学学报,2004,39(5):336-339. 被引量：2

二级参考文献19

  • 1Clevenger C, Thickman K,Ngo W et al. Role of BAG-1 in the survival and proliferation of the cytokine-dependent lymphocyte lines, Ba/F3 and Nb2. Mol Endocrinol, 1997;11(5):608～18
  • 2Liu R, Takayama S, Zheng Y et al. Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in cancer cells. J Biol Chem, 1997; 273:16985～92
  • 3Cutress RI, Townsend PA,Sharp A et al. BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. Oncogene,2003;22(32):4973～82
  • 4Bardelli A,Longati P,Albero D et al. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J,1996;15(22):6205～12
  • 5Tang SC. BAG-1: an anti-apoptotic tumour marker. IUBMB Life, 2002; 53(2): 99-105
  • 6Driscoll L,Linehan R,Kennedy M et al: Lack of prognostic significance of survivin, survivin-delfaEx3, survivin-2B,galectin-3,bag-1,bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett,2003;201(2):225～36
  • 7Tang SC, Shaheta N, Chernenko G et al. Expression of BAG-1 in invasive breast carcinomas. J Clin Oncol, 1999; 17(6):1710～9
  • 8Takayama S, Sato T, Krajewski S et al. Cloning and functional analysis of BAG-1: a novel Bcl-2 binding protein with anti-cell death activity. Cell, 1995;80(2):279～84
  • 9Sondermann H, Scheufler C, Schneider C et al. Structure of a Bag/Hsc70 complex: convergent functional evolution of Hsp70 nucleotide exchange factors. Science,2001; 291(5508):1553～7
  • 10Sondermann H,Ho AK,Listenberger LL et al.Prediction of novel Bag-1 homologs based on structure/function analysis identifies Snl1p as an Hsp70 co-chaperone in saccharomyces cerevisiae. J Biol Chem,2002; 277(36): 33220～7

共引文献1

同被引文献34

  • 1周则卫,沈秀.蛇床子素药理活性的研究概况[J].中国新药杂志,2006,15(20):1726-1730. 被引量：33
  • 2陈立慧,朱丽萍,武静.女性激素与乳腺癌[J].中国现代医生,2007,45(07Z):90-91. 被引量：12
  • 3吴随群,赵伟.肺癌MMP2和MMP9、VEGF在非小细胞肺癌中的表达和意义[J].肿瘤基础与临床,2007,20(1):12-14. 被引量：12
  • 4Kronqvist P, Kuopio T, Jalava P, et al.Morphometrical malignancy grading is a valuable prognostic factor in invasive ductal breast cancer[J].Br J Cancer, 2002,87(11):1275-80.
  • 5Goldhirsch A, Wood W C, Coates A S, et al.Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St.Gallen international expert consensus on the primary therapy of early breast cancer 2011[J].Ann Oncol, 2011,22(8):1736-47.
  • 6Perou C M, Sorlie T, Eisen M B, et al.Molecular portraits of human breast tumors[J].Nature, 2000,406(6797):747-52.
  • 7Eskelinen M, Lipponen P, Marin S, et al.Prognostic factors in human pancreatic cancer, with special reference to quantitative histology[J].Scand J Gastroenterol, 1991,26(5):483-90.
  • 8Rudas M, Neumayer R, Gnant M F, et al.p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast[J].Eur J Cancer, 1997,33(1):39-44.
  • 9Ihemelandu C U, Leffall L D Jr, Dewitty R L, et al.Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival[J].J Surg Res, 2007,143(1):109-18.
  • 10Zajdela A, De LaRiva J, Ghossein N.The relation of prognosis to the nuclear diameter of breast cancer cells obtained by cytologic aspiration[J].Acta Cytol, 1979,23(1):75-80.

引证文献5

二级引证文献6

安徽医科大学学报
2009年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部